Irlab Therapeutics’ oral therapy IRL757 was safe and well tolerated in healthy volunteers in the first part of a Phase 1 study testing the therapy, a potential treatment for apathy in patients with Parkinson’s disease and other neurological conditions. “This bodes well for the further clinical development of a…
Two studies support the safety and tolerability of Nuplazid (pimavanserin) in older or frail adults with psychosis associated with Parkinson’s disease. Safety data on Nuplazid, the only medication approved by the U.S. Food and Drug Administration (FDA) to treat Parkinson’s-associated psychosis, were presented at this year’s International…
Aspen Neuroscience has opened a manufacturing facility for ANPD001, its investigational stem cell therapy for Parkinson’s disease being used in an ongoing Phase 1/2a clinical trial. The 22,000-square-foot facility is an expansion of the company’s headquarters near San Diego, and is reported to include three manufacturing suites certified…
App-based consumer technology like Rune Labs’ StrivePD may help people with Parkinson’s disease feel more confident in managing their symptoms, bridging the gap in specialty care by providing continuous monitoring, according to the results of a pilot program done in collaboration with Kaiser Permanente. Patients in the program…
Changes in the levels of thyroid hormones in the bloodstream are related to cognitive impairments in people with Parkinson’s disease, according to a new study by researchers in China. “Our findings provided definite proof that changes in thyroid hormone levels have clinical implications for cognitive outcomes” in Parkinson’s,…
Exposure to air pollutants, such as fine particulate matter and nitrogen dioxide, may increase the risk of developing Parkinson’s disease and dyskinesia, or involuntary movements, according to a study using data from the Rochester Epidemiology Project. These findings add to growing evidence that breathing polluted air is a…
GT-02287, a potential therapy for Parkinson’s disease, showed promising results in a Phase 1 clinical trial involving healthy volunteers, according to data announced by developer Gain Therapeutics. The investigational treatment was found to be safe and well tolerated at doses projected to be effective in people with the neurodegenerative…
Note: This story was updated Oct. 7, 2024, to correct references to the open-label extension study of the BounDNless trial. A year of treatment with ND0612, an investigational liquid formulation of levodopa/carbidopa continuously administered as an infusion under the skin, sustainably reduced the periods of time when motor symptoms…
A neural platform based on graphene, a strong but extremely thin carbon sheet that Inbrain Neuroelectronics is developing for a surgical treatment of Parkinson’s disease, was used for a first time on a patient undergoing brain tumor surgery. The platform’s graphene-based brain-computer interface (BCI) technology demonstrated an ability…
Genetic variants found in the DNA of mitochondria, the cell compartments that produce energy, were associated with the severity of Gulf War Illness (GWI), a chronic condition seen in Gulf War veterans that’s associated with environmental toxin exposure, a study found. The research team, led by scientists at the…
Get regular updates to your inbox.
